Immune-Onc Therapeutics is founded in 2016, operates from its headquarter in 795 San Antonio Rd Palo Alto, California 94303, US. The company operates in the Business Services, Research & Development sector.
Immune-Onc Therapeutics specializes in Drug development, Biotherapeutic discovery, Clinical-stage oncology, Targeting myeloid cell inhibitory receptors, Pipeline development, and offers services including Antagonist antibody targeting LILRB2 (IO-108), Antagonist antibody targeting LILRB4 (IO-202), and First-in-class antagonist antibody targeting LAIR1 (IO-106).
Total Rounds
US$ 25M
Last Round
US$ 25M
Rounds
1
Investors
TriWise Capital, Other investors